|
| Author | Year | Origin | Population | Study type | Study period | Total patients | N=CKD | Intervention | Cured patients | Recurrence | Outcome measures |
|
| Mullane | 2013 | Department of Medicine, University of Chicago, Chicago | Renal impairment and CDI | Randomized controlled trials | 2012 | 1054 | 321 | Fidaxomycin 158
Vancomycin 163 | 252
(78.5%) | 66
26% | (i) Clinical cure
(ii) Sustained response
(iii) Recurrence
(iv) Mortality |
| Lachowicz | 2014 | Department of Medical Microbiology, Medical University of Warsaw | Dialysis patients | Retrospective non-RCT (observational study) | November 2012–December 2012 | 9 | 9 | Environmental decontamination (chlorine bleach, indomethacin, octenisept, and hydrogen peroxide vapour)
Isolation | 4 | 3 | (i) Spread of infection
(ii) Microbiological analysis
(iii) Mortality |
| Kujawa | 2015 | Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice | Kidney transplant and immunosuppressive therapy | Retrospective non-RCT (observational study) | October 2012–October 2013 and December 2013–December 2014 | 23 | 17 | Lactobacillus
Plantarum 299v | N/A | N/A | (i) C. difficile infection incidence
(ii) Mortality
(iii) Severity of CDI
(iv) Duration of diarrhea
(v) Number of stools per day
(vi) Average CRP serum concentration |
| Cammarota [31] | 2015 | Department of Internal Medicine, a.Gemelli University Hospital Roma, Italy | Recurrent C. difficile patients | Randomized controlled trial | July 2013-June 2014 | 39 | 20 | Faecal microbiota transplantation by colonoscopy
Vancomycin | 18
(90%) | 2
(10%) | (i) Recurrence rate of C. difficile infection with FMT and vancomycin |
|
